Recent important trials of pharmacotherapy in Parkinson's disease.

Abstract:

:Parkinson's disease (PD) affects approximately 1% of individuals > 60 years. Of these PD patients approximately 40% suffer dementia in later life. Levodopa is commonly used in the treatment of PD. Experimental evidence suggests that the dopamine synthesised from levodopa may contribute to the further degeneration of dopaminergic neurons. The results of the clinical outcome part of the Earlier Versus Later Levodopa Therapy in PD study suggest that levodopa slows the progression of PD. In contrast, the single photon emission-computed tomography imaging substudy was not conclusive but suggested that levodopa hastened the progression of PD. Thus, further studies of the effects of levodopa on the progression of PD are needed before it can be proved that levodopa does not have a detrimental effect on dopaminergic neurons. In a clinical trial of the anticholinesterase rivastigmine, a small improvement was observed in some patients suffering from dementia associated with PD. This small benefit has to be balanced against cholinergic side effects and a possible loss of efficacy of antimuscarinic agents used for motor control in PD.

authors

Doggrell SA

doi

10.1517/14656566.6.6.1025

keywords:

subject

Has Abstract

pub_date

2005-06-01 00:00:00

pages

1025-8

issue

6

eissn

1465-6566

issn

1744-7666

journal_volume

6

pub_type

杂志文章,评审
  • Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.

    abstract:INTRODUCTION:Over the past decade, treatment options for men with metastatic castration-resistant prostate cancer (CRPC) have expanded with the addition of abiraterone acetate (AA), enzalutamide, sipuleucel-T, radium-223, docetaxel and cabazitaxel. The optimal sequencing of therapies in the context of efficacy and know...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.995090

    authors: Zhang T,Zhu J,George DJ,Armstrong AJ

    更新日期:2015-03-01 00:00:00

  • Pharmacotherapy of large B-cell lymphoma.

    abstract:BACKGROUND:Constituting approximately 30% of lymphoid malignancies, diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma in adults worldwide. The clinical and biologic heterogeneity that exists in DLBCL suggests that this entity might actually be comprised of several distinct neoplasms that coul...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.13.2247

    authors: Escalón MP,Lossos IS

    更新日期:2008-09-01 00:00:00

  • Pharmacologic treatment of male breast cancer.

    abstract::Male breast cancer is an uncommon condition. It often occurs in settings in which there is an imbalance between androgens and oestrogens. Genetics plays an important role, as many cases are associated with mutations in BRCA2 or other genes. Male breast cancer occurs at an older age than female breast cancer and is fre...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903200634

    authors: Hayes TG

    更新日期:2009-10-01 00:00:00

  • TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept.

    abstract::There is accumulating evidence that tumour necrosis factor (TNF) plays a major role in the pathogenesis of rheumatoid arthritis (RA). Recent biotechnological advances have allowed for the development of agents that directly target TNF, a pro-inflammatory cytokine. In the last 2 years, the US FDA and the EU's Commissio...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.1.75

    authors: Mikuls TR,Moreland LW

    更新日期:2001-01-01 00:00:00

  • Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.

    abstract:INTRODUCTION:The introduction of novel agents has significantly improved multiple myeloma (MM) patient outcome during the last two decades. MM received the most drug approvals for any one malignancy during this time period, both in the United States as well as in Europe. Areas covered: Proteasome inhibitors, immunomodu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1340942

    authors: Podar K,Pecherstorfer M

    更新日期:2017-08-01 00:00:00

  • Pharmacological management of pulmonary embolism.

    abstract:INTRODUCTION:Pulmonary embolism (PE) is a common and potentially severe manifestation of venous thromboembolism. Its management has relied on anticoagulation by vitamin K antagonists (VKA) for the past fifty years. Recently, new alternative drugs have been developed and dramatically modified both the treatment of acute...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1268122

    authors: Gouin B,Robert-Ebadi H,Righini M,Blondon M

    更新日期:2017-01-01 00:00:00

  • Pharmacological management of axial spondyloarthritis in adults.

    abstract::Introduction: Spondyloarthritis (SpA) refers to a group of disorders sharing common clinical, genetic and imaging characteristics. Axial (ax) SpA corresponds to a subgroup that mainly affects the axial skeleton, leading to inflammatory back pain and progressive radiographic changes of the sacroiliac joints and the spi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1617853

    authors: Toussirot E

    更新日期:2019-08-01 00:00:00

  • Economic assessment in the management of non-Hodgkin's lymphoma.

    abstract::An increasing need for economic evaluations of non-Hodgkin's lymphoma (NHL) treatments exists. We performed a literature review on the currently available NHL economic evaluations, using PubMed and the Cochrane database. English and Dutch language papers on treatment in adults were selected. A total of 88 publications...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.12.2529

    authors: van Agthoven M,Uyl-de Groot CA,Sonneveld P,Hagenbeek A

    更新日期:2004-12-01 00:00:00

  • An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma.

    abstract:INTRODUCTION:Hepatocellular carcinoma (HCC) is a frequent and severe complication of cirrhosis. Most HCC patients initially present with or progress to advanced stage disease and require systemic treatment. As hypervascularization is a major characteristic of HCC, antiangiogenic drugs have been tested. Areas covered: I...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1378346

    authors: Raoul JL,Gilabert M,Adhoute X,Edeline J

    更新日期:2017-10-01 00:00:00

  • Fluticasone propionate: a potent inhaled corticosteroid for the treatment of asthma.

    abstract::Fluticasone propionate (FP) is a potent inhaled corticosteroid (ICS) for the treatment of asthma. It is currently marketed in both the United States (as Flovent) and Europe (as Flixotide). Fluticasone is available in both aerosolised metered dose inhaler (MDI) and dry powder devices, with dosages ranging from 44-500 m...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.6.1227

    authors: Staresinic AG,Sorkness CA

    更新日期:2000-09-01 00:00:00

  • Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer.

    abstract::Developments in the role of adjuvant and neoadjuvant chemotherapy for the treatment of patients with breast cancer have focused on the taxes, in particular, docetaxel. This paper discusses the rationale for the introduction of docetaxel into the management of patients following surgery and also its role in those patie...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.10.2147

    authors: Heys SD,Sarkar T,Hutcheon AW

    更新日期:2004-10-01 00:00:00

  • Pharmacological management of malignant hypertension.

    abstract:INTRODUCTION:According to current guidelines, malignant hypertension is one of the emergencies in hypertension. The definition requires the presence of bilateral retinal hemorrhages or exudates, with or without papilledema, acute heart failure and acute deterioration in renal function in severe hypertension. Patients w...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1732923

    authors: Lewek J,Bielecka-Dąbrowa A,Maciejewski M,Banach M

    更新日期:2020-07-01 00:00:00

  • Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy.

    abstract::Diabetes mellitus has reached epidemic proportions in many countries and is the most common cause of end stage renal disease (ESRD). The angiotensin II receptor-1 (AT(1)) antagonists losartan and irbesartan have recently been evaluated as renoprotective agents in large clinical trials of patients with Type 2 diabetes ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.3.5.625

    authors: Doggrell SA

    更新日期:2002-05-01 00:00:00

  • Pharmacological management of transient synovitis.

    abstract::Synovitis is a painful and, occasionally, disabling disease. Patients with synovitis, especially new onset synovitis, should be referred to a rheumatologist urgently so that they can be assed and treated as quickly as possible. Clinical assessment and investigations are required to help differentiate between transient...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.1.35

    authors: Sokoll KB,Helliwell P

    更新日期:2006-01-01 00:00:00

  • Current and Emerging Pharmacotherapy for Chronic Spontaneous Urticaria: A Focus on Non-biological Therapeutics.

    abstract:INTRODUCTION:Chronic spontaneous urticaria (CSU) refers to urticaria (wheals) or angioedema, which occur for a period of six weeks or longer without an apparent cause. The condition may impair the patient's quality of life. AREAS COVERED:Treatment for CSU is mainly symptomatic. Both AAAAI/ACAAI practice parameters and...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1829593

    authors: Hon KL,Li JTS,Leung AKC,Lee V

    更新日期:2020-09-29 00:00:00

  • The management of acute diarrhea in children in developed and developing areas: from evidence base to clinical practice.

    abstract:INTRODUCTION:Acute diarrhea remains a major problem in children and is associated with substantial morbidity, mortality and costs. While vaccination against rotavirus could reduce the burden of the disease, the persistent impact of intestinal infections requires effective treatment in adjunct to oral rehydration soluti...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.634800

    authors: Guarino A,Dupont C,Gorelov AV,Gottrand F,Lee JK,Lin Z,Lo Vecchio A,Nguyen TD,Salazar-Lindo E

    更新日期:2012-01-01 00:00:00

  • Treating diabetic ulcers.

    abstract:INTRODUCTION:Diabetic foot ulceration is a serious secondary complication of diabetes mellitus and the most common cause of hospitalization in diabetic patients. The etiology of diabetic foot ulcerations is complex due to their multifactorial nature. Thus, addressing all of the factors involved remains instrumental in ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.530658

    authors: Tecilazich F,Dinh T,Veves A

    更新日期:2011-03-01 00:00:00

  • Daclatasvir for the treatment of chronic hepatitis C.

    abstract:INTRODUCTION:Following more than 20 years of Interferon (IFN)-based treatment for hepatitis C virus (HCV), the understanding of viral life cycle led to the development of new antiviral drugs directly targeting HCV replication steps. Daclatasvir (DCV) is a potent inhibitor of non-structural NS5A HCV protein with pangeno...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1109631

    authors: Degasperi E,Aghemo A,Colombo M

    更新日期:2015-01-01 00:00:00

  • Pemetrexed for the treatment of non-small cell lung cancer.

    abstract:INTRODUCTION:Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death worldwide. Although advanced NSCLC is still incurable, various anti-neoplastic agents have become available for the treatment of this disease. Pemetrexed , a multi-target folate antagonist, has improved the survival of non-squamous...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.802774

    authors: Genova C,Rijavec E,Truini A,Coco S,Sini C,Barletta G,Dal Bello MG,Alama A,Savarino G,Pronzato P,Boccardo F,Grossi F

    更新日期:2013-08-01 00:00:00

  • New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.

    abstract:BACKGROUND:Sitagliptin is a highly selective oral dipeptidyl peptidase-4 inhibitor. This drug increases the plasma concentration of active glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide. These two hormones then simulate the secretion of insulin in a glucose-dependent manner and inhibit glu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.9.1495

    authors: Gagliardino JJ,Santoro S,Arellano S,Di Girolamo G

    更新日期:2008-06-01 00:00:00

  • Topical alprostadil cream for the treatment of erectile dysfunction.

    abstract::Erectile dysfunction (ED) has serious negative consequences on both sexual experience and emotional well being and affects a broad range of age groups. The prevalence of ED is associated with increasing age and has been reported to be as high as 70%. Although the disorder is common and underdiagnosed, its treatment ca...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.3.623

    authors: Becher E

    更新日期:2004-03-01 00:00:00

  • New treatment options for panic disorder: clinical trials from 2000 to 2010.

    abstract:INTRODUCTION:Panic disorder (PD) is a prevalent psychiatric disorder characterized by unexpected and recurrent panic attacks. PD patients present significant psychosocial impairment and a high risk of psychiatric comorbidities and suicide. PD should be treated effectively as soon as the symptoms emerge because the long...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.562200

    authors: Freire RC,Hallak JE,Crippa JA,Nardi AE

    更新日期:2011-06-01 00:00:00

  • Therapeutic options for Acinetobacter baumannii infections.

    abstract::Acinetobacter baumannii is an important cause of nosocomial infections, mainly in patients in intensive care units. This microorganism, although with slight differences depending on the country, presents resistance to multiple antimicrobial agents, occasionally including resistance to colistin: hence, it can be consid...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.4.587

    authors: Vila J,Pachón J

    更新日期:2008-03-01 00:00:00

  • Metformin & lifestyle intervention prevent Type 2 diabetes: lifestyle intervention has the greater effect.

    abstract::Diabetes mellitus is now occurring in epidemic proportions in many countries. Owing to the limited effectiveness of drug prophylaxis of diabetic complications after diabetes has developed, it may be more appropriate to investigate ways to prevent the onset of diabetes. A recent trial published by the Diabetes Preventi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.3.7.1011

    authors: Doggrell SA

    更新日期:2002-07-01 00:00:00

  • Pharmacological management of paracoccidioidomycosis.

    abstract::A systemic and endemic emerging mycosis in Latin America, paracoccidioidomycosis, is characterised by its chronicity and by the severity of the disseminated form in healthy individuals, as well as in immunocompromised individuals co-infected with HIV, resulting, in the latter, in a mortality rate in the range of 30 - ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.3.385

    authors: Yasuda MA

    更新日期:2005-03-01 00:00:00

  • Alprazolam extended-release in panic disorder.

    abstract::Alprazolam-XR is an extended-release formulation of alprazolam designed to deliver sustained therapeutic concentrations for 24 h after once-daily dosing. Plasma concentrations gradually decline as the time for the next dose approaches, but still remain above therapeutic minimum levels. The anti-panic efficacy of alpra...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 临床试验,杂志文章

    doi:10.1517/14656566.5.7.1599

    authors: Rickels K

    更新日期:2004-07-01 00:00:00

  • The role of aspirin in cardiovascular diseases--forgotten benefits?

    abstract::The increasing burden of cardiovascular diseases in developed, as well as developing countries, underscores the need for the more widespread and appropriate use of aspirin in secondary prevention of occlusive vascular events during acute evolving myocardial infarction (MI) and in primary prevention. Aspirin should be ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.1.109

    authors: Williams A,Hennekens CH

    更新日期:2004-01-01 00:00:00

  • Management of insomnia in alcohol use disorder.

    abstract::Introduction: Insomnia has been implicated in the development, maintenance, worsening, and relapse of alcohol use disorder (AUD).Areas covered: The authors review the possible pharmacological and non-pharmacological treatment options of insomnia for patients with alcohol-use disorder and provide their expert opinion.E...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1705279

    authors: Geoffroy PA,Lejoyeux M,Rolland B

    更新日期:2020-02-01 00:00:00

  • Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?

    abstract:INTRODUCTION:Historically, there were few effective and durable treatments for metastatic melanoma. Recently, mutation based targeted therapies have revolutionized treatment and outcomes for patients with metastatic melanoma. Specifically, inhibitors aimed at BRAF, NRAS, and C-KIT mutations are now commonly used in tre...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1299710

    authors: Turner MC,Rossfeld K,Salama AK,Tyler D,Beasley G

    更新日期:2017-04-01 00:00:00

  • Olanzapine pamoate for the treatment of schizophrenia.

    abstract:INTRODUCTION:Nonadherence is still a major problem in the long-term treatment of schizophrenia. Long-acting injectable or depot atypical antipsychotics are associated with better maintenance. Olanzapine pamoate, available since 2010, is the second depot atypical antipsychotic. AREAS COVERED:This review covers data on ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.553193

    authors: Naber D

    更新日期:2011-03-01 00:00:00